USTEKINUMAB: A GENETICALLY ENGINEERED BIOLOGIC FOR PSORIASIS TREATMENT – A CASE REPORT

Abstract

Introduction: One of the critical challenges in modern dermatology is ensuring the effectiveness of treatment for patients 
with moderate-to-severe psoriasis. The introduction of genetically engineered biological therapies targeting specific pro
inflammatory cytokines has significantly advanced the management of this condition and improved patients' quality of life.  
The aim of the study is to evaluate the clinical effectiveness of ustekinumab in a patient with severe psoriasis. 
Materials and Methods: A retrospective case analysis was conducted using the medical records of a single patient who 
received inpatient treatment at the dermatovenereology department of City Hospital № 2, under the Abay Regional Health 
Authority. The patient's condition was monitored through the Comprehensive Medical Information System (CMIS) during the 
period from 2011 to 2024. Diagnostic and therapeutic procedures were performed in accordance with the approved clinical 
protocol of the Ministry of Health of the Republic of Kazakhstan № 172, dated October 14, 2022. The publication of treatment 
outcomes was authorized by the hospital administration and the patient through signed informed consent. 
Results: After the addition of Stelara to standard anti-inflammatory therapy, the patient’s condition improved significantly. 
The drug alleviated symptoms such as skin itching, rashes, and joint pain. Clinical studies have demonstrated that 
ustekinumab effectively controls disease progression and enhances patients’ quality of life by reducing pro-inflammatory 
cytokines and modulating anti-inflammatory markers. Research has also confirmed its efficacy in treating psoriatic arthritis 
symptoms and its success across diverse populations, with 67.2% of patients achieving PASI75 after two doses.  
Conclusion: This clinical case demonstrates the effectiveness of ustekinumab in treating moderate-to-severe psoriasis 
complicated by psoriatic arthritis. The improvement in skin lesions, joint symptoms, and overall patient condition highlights 
the potential of biological therapy in disease management and enhancing quality of life.